XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers, issued by the FASB. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

•Step 1: Identify the contract with the customer
•Step 2: Identify the performance obligations in the contract
•Step 3: Determine the transaction price
•Step 4: Allocate the transaction price to the performance obligations in the contract
•Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by Rockwell from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
Rockwell operates in one market segment, the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Rockwell's customer mix is diverse, with most customer sales concentrations under 10%. For the three months ended September 30, 2025, revenues from sales to two customers, DaVita, Inc. ("DaVita") and another customer were approximately 12% and 11% of total revenues for the period, respectively, and 17% and 10% of total revenues for the nine months ended September 30, 2025, respectively. For the three months ended September 30, 2024, revenues from DaVita was 52% of total revenues for the period, and 47% of total revenues for the nine months ended September 30, 2024. At September 30, 2025, DaVita represented 12% of the total net consolidated accounts receivable balance. At December 31, 2024, DaVita represented 20% of the total net consolidated accounts receivable balance. See below for additional information regarding the Company's contract with DaVita.
Product Sales
The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.
For the majority of the Company's international customers, the Company recognizes revenue when the customer takes control at the shipping point, which is generally the Company's plant or warehouse. For other customers, the Company recognizes revenue based on when the customer takes control of the product upon delivery. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers estimated at the time of sale. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while a small subset of customers have payment terms averaging 60 days.
Deferred License Revenue
The Company received upfront fees under three distribution and license agreements, which were recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey to determine that regulatory approval was probable as of the execution of the agreement. During the nine months ended September 30, 2025, all remaining deferred
revenue relating to the distribution and license agreements was recognized, resulting in $0.3 million of revenue recorded. All license agreements have been terminated.
Product Purchase Agreement
On September 18, 2023, Rockwell and its long-time customer, DaVita, a provider of kidney care, entered into an Amended and Restated Products Purchase Agreement (the "Amended Agreement"), which amends and restates the Product Purchase Agreement, dated July 1, 2019, as amended, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amended Agreement, the Company and DaVita agreed to an increase in product pricing, effective September 1, 2023. The term of the Amended Agreement was scheduled to expire on December 31, 2024. Prior to the expiration, the Company received written notice from DaVita, notifying the Company that DaVita intended to extend the term of the Amended Agreement through December 31, 2025 (the "Extension Term"). However, DaVita subsequently indicated that it will completely transition to another supplier, subject to further discussion between Rockwell and DaVita. DaVita has agreed to quarterly, non-refundable payments totaling $1.7 million during the nine months ended September 30, 2025 to ensure supply continuity during the transition period for products purchased. These quarterly, non-refundable payments of $0.4 million and $1.7 million were recorded as revenue during the three and nine months ended September 30, 2025, respectively. Discussions between Rockwell and DaVita are ongoing and the Company continues to supply DaVita as of the filing date of this report.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousandsThree Months Ended September 30, 2025Nine Months Ended September 30, 2025
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
License Fee – Over Time$— $— $— $325 $— $325 
Total Drug Products— — — 325 — 325 
Concentrate Products
Product Sales – Point-in-time15,927 13,824 2,103 50,587 44,449 6,138 
Total Concentrate Products15,927 13,824 2,103 50,587 44,449 6,138 
Net Revenue$15,927 $13,824 $2,103 $50,912 $44,449 $6,463 

In thousandsThree Months Ended September 30, 2024Nine Months Ended September 30, 2024
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
License Fee – Over Time$11 $— $11 $34 $— $34 
Total Drug Products11 — 11 34 — 34 
Concentrate Products
Product Sales – Point-in-time28,305 26,247 2,058 76,790 70,390 6,400 
Total Concentrate Products28,305 26,247 2,058 76,790 70,390 6,400 
Net Revenue$28,316 $26,247 $2,069 $76,824 $70,390 $6,434 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousandsSeptember 30, 2025December 31, 2024January 1, 2024
Accounts Receivable, net$8,328 $8,291 $10,901 
Contract Liabilities, which are included in deferred license revenue$— $475 $521 
There were no other material contract assets recorded on the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024. The Company does not generally accept returns of its concentrate products and no material provision for returns of concentrates products was established as of September 30, 2025 or December 31, 2024. 
Transaction price allocated to remaining performance obligations
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was nil as of September 30, 2025. The Company applies the practical expedient in ASC 606, paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.